Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naïve Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks’ treatment, comparative study

吡格列酮 罗格列酮 医学 耐受性 安慰剂 2型糖尿病 外周水肿 不利影响 内科学 糖尿病 随机对照试验 泌尿科 内分泌学 替代医学 病理
作者
Masatoshi Kikuchi,Kohei Kaku,Masato Odawara,Shin‐ichi Momomura,Ryutaro Ishii
出处
期刊:Current Medical Research and Opinion [Informa]
卷期号:28 (6): 1007-1016 被引量:7
标识
DOI:10.1185/03007995.2012.694361
摘要

Objective:A 28-week, randomized, placebo-controlled study was performed to evaluate efficacy and tolerability of rosiglitazone in Japanese type 2 diabetes patients.Research and design methods:373 patients were randomized to rosiglitazone (4–8 mg/day), pioglitazone (15–45 mg/day) or placebo. Agents were titrated to maximum doses at fixed time points in a pre-defined manner. Primary endpoints were superiority of each active treatment compared to placebo in HbA1c at week 16, and non-inferiority between active agents in HbA1c at week 28, based on a −0.45% margin.Results:At week 16, improvements versus placebo were observed with rosiglitazone 4 mg/day (−0.96%, p < 0.001) and pioglitazone 30 mg/day (−1.26%, p < 0.001). At week 28, rosiglitazone and pioglitazone were associated with significant changes from baseline of −0.94% and −1.35%, respectively and rosiglitazone produced statistically and clinically significant improvement versus placebo (−1.29%, CI: −1.62, −0.97). Pioglitazone also showed significant improvement versus placebo (−1.64%, CI: −1.96, −1.31). Non-inferiority of rosiglitazone (4–8 mg/day) to pioglitazone (30–45 mg/day) was not demonstrated (treatment-difference: −0.41%, 95% CI: −0.64, −0.18).More patients treated with pioglitazone were withdrawn from the study by adverse events compared with rosiglitazone (14 vs. 4, p = 0.015). Pioglitazone was associated with higher incidences of adverse events relating to edema and weight gain compared with rosiglitazone (edema: 25.2 vs. 11.3%, weight gain: 9.4 vs. 4.4%). There were no reports of ischemic heart disease or congestive heart failure in any treatment group.Conclusion:Although non-inferiority to pioglitazone up to 45 mg in efficacy was not shown, rosiglitazone was confirmed to have clinically meaningful efficacy over placebo and fewer fluid-related events than pioglitazone.Trial registration: ClinicalTrials.gov identifier: NCT00297063.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zyyyy发布了新的文献求助10
2秒前
HGQ应助科研通管家采纳,获得10
3秒前
脑洞疼应助科研通管家采纳,获得10
3秒前
科研通AI2S应助科研通管家采纳,获得10
3秒前
Orange应助科研通管家采纳,获得10
3秒前
3秒前
爆米花应助科研通管家采纳,获得10
3秒前
烟花应助科研通管家采纳,获得30
3秒前
3秒前
future完成签到 ,获得积分10
6秒前
小罗完成签到 ,获得积分0
6秒前
John完成签到 ,获得积分10
7秒前
7秒前
BIGer发布了新的文献求助10
9秒前
白色蒲公英完成签到,获得积分10
9秒前
852应助甜美的芷采纳,获得10
10秒前
小徐同学发布了新的文献求助10
12秒前
14秒前
swiftie139完成签到,获得积分10
14秒前
思源应助有风的晴天采纳,获得10
16秒前
16秒前
18秒前
18秒前
田静然完成签到,获得积分10
19秒前
20秒前
Ninomae完成签到,获得积分10
20秒前
zyyyy发布了新的文献求助10
20秒前
壹号发布了新的文献求助10
21秒前
甜美的芷完成签到,获得积分10
21秒前
22秒前
22秒前
22秒前
22秒前
甄冰海完成签到,获得积分10
23秒前
zjw发布了新的文献求助10
23秒前
轻松方盒完成签到,获得积分20
24秒前
甄冰海发布了新的文献求助10
27秒前
甜美的芷发布了新的文献求助10
27秒前
27秒前
神启发布了新的文献求助10
28秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2000
Very-high-order BVD Schemes Using β-variable THINC Method 1200
中国荞麦品种志 1000
BIOLOGY OF NON-CHORDATES 1000
Autoregulatory progressive resistance exercise: linear versus a velocity-based flexible model 550
The Collected Works of Jeremy Bentham: Rights, Representation, and Reform: Nonsense upon Stilts and Other Writings on the French Revolution 320
Discourse, Identities and Genres in Corporate Communication 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3359630
求助须知:如何正确求助?哪些是违规求助? 2982355
关于积分的说明 8703259
捐赠科研通 2664021
什么是DOI,文献DOI怎么找? 1458787
科研通“疑难数据库(出版商)”最低求助积分说明 675243
邀请新用户注册赠送积分活动 666331